Parmar D - Search Results

1

Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients.

Siddiqui MS, Parmar D, Shaikh F, Forsgren M, Patel S, Bui AT, Boyett S, Patel V, Sanyal AJ. Siddiqui MS, et al. Among authors: parmar d. Liver Transpl. 2023 Sep 1;29(9):979-986. doi: 10.1097/LVT.0000000000000110. Epub 2023 Feb 28. Liver Transpl. 2023. PMID: 36847136

2

Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study.

Parmar DV, Kansagra KA, Patel JC, Joshi SN, Sharma NS, Shelat AD, Patel NB, Nakrani VB, Shaikh FA, Patel HV; on behalf of the ZYAN1 Trial Investigators. Parmar DV, et al. Am J Nephrol. 2019;49(6):470-478. doi: 10.1159/000500232. Epub 2019 May 21. Am J Nephrol. 2019. PMID: 31112954 Clinical Trial.

3

A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis.

Siddiqui MS, Idowu MO, Parmar D, Borg BB, Denham D, Loo NM, Lazas D, Younes Z, Sanyal AJ. Siddiqui MS, et al. Among authors: parmar d. Clin Gastroenterol Hepatol. 2021 Dec;19(12):2670-2672. doi: 10.1016/j.cgh.2020.10.051. Epub 2020 Nov 2. Clin Gastroenterol Hepatol. 2021. PMID: 33152542 Clinical Trial.

4

A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis.

Vuppalanchi R, González-Huezo MS, Payan-Olivas R, Muñoz-Espinosa LE, Shaikh F, Pio Cruz-Lopez JL, Parmar D. Vuppalanchi R, et al. Among authors: parmar d. Clin Transl Gastroenterol. 2021 Mar 26;12(4):e00327. doi: 10.14309/ctg.0000000000000327. Clin Transl Gastroenterol. 2021. PMID: 33769355 Free PMC article.

5

Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.

Vuppalanchi R, Caldwell SH, Pyrsopoulos N, deLemos AS, Rossi S, Levy C, Goldberg DS, Mena EA, Sheikh A, Ravinuthala R, Shaikh F, Bainbridge JD, Parmar DV, Chalasani NP. Vuppalanchi R, et al. Among authors: parmar dv. J Hepatol. 2022 Jan;76(1):75-85. doi: 10.1016/j.jhep.2021.08.025. Epub 2021 Sep 4. J Hepatol. 2022. PMID: 34487750 Clinical Trial.

6

Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial.

Rodriguez-Gutierrez R, González JG, Parmar D, Shaikh F, Cruz-López P. Rodriguez-Gutierrez R, et al. Among authors: parmar d. J Lipid Res. 2022 Jul;63(7):100233. doi: 10.1016/j.jlr.2022.100233. Epub 2022 May 21. J Lipid Res. 2022. PMID: 35605678 Free PMC article. Clinical Trial.

7

Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.

Siddiqui MS, Parmar D, Sheikh F, Sarin SK, Cisneros L, Gawrieh S, Momin T, Duseja A, Sanyal AJ. Siddiqui MS, et al. Among authors: parmar d. Clin Gastroenterol Hepatol. 2023 Sep;21(10):2597-2605.e2. doi: 10.1016/j.cgh.2023.01.018. Epub 2023 Jan 31. Clin Gastroenterol Hepatol. 2023. PMID: 36731585

8

Pharmacokinetics and Safety Evaluation of Single-Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment.

Lawitz E, Parmar D, Momin T, Shaikh F, Patel H, Hayes H, Swint K. Lawitz E, et al. Among authors: parmar d. Clin Pharmacol Drug Dev. 2023 Dec;12(12):1142-1155. doi: 10.1002/cpdd.1339. Epub 2023 Nov 1. Clin Pharmacol Drug Dev. 2023. PMID: 37909052 Clinical Trial.

9

New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.

Kaul U, Parmar D, Manjunath K, Shah M, Parmar K, Patil KP, Jaiswal A. Kaul U, et al. Among authors: parmar d, parmar k. Cardiovasc Diabetol. 2019 Jun 17;18(1):80. doi: 10.1186/s12933-019-0884-3. Cardiovasc Diabetol. 2019. PMID: 31208414 Free PMC article. Review.

10

Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.

Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Gawrieh S, et al. Among authors: parmar d. Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843. Epub 2021 Jul 19. Hepatology. 2021. PMID: 33811367 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

490 results

Search Page